clinical trial · NCT05557409
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
Agitation in Patients With Dementia of the Alzheimer's TypeAlzheimer DiseaseAgitationAXS-05Placebo
brief summary
This trial was a multi-center, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of AXS-05 compared to placebo for the treatment of agitation associated with Alzheimer's disease.
started
Sep 6, 2022
primary completion
Nov 21, 2024
completion
Dec 21, 2024
last updated
Aug 13, 2026
detailed description
Eligible subjects were randomized in a 1:1 ratio for up to 5 weeks to be treated with AXS-05 or placebo.
official title
ADVANCE-2: Addressing Dementia Via Agitation-Centered Evaluation 2: A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Alzheimer's Disease Agitation
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol